Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study

home / between-the-lines / tivozanib-plus-nivolumab-vs-tivozanib-monotherapy-in-rcc-following-an-immune-checkpoint

Experts discuss the phase 3 TiNivo-2 study comparing tivozanib plus nivolumab vs tivozanib monotherapy in renal cell carcinoma following prior immune checkpoint inhibitor treatment.

EP. 1: First-Line RCC Treatment in 2025: Navigating the Evolving Therapeutic Landscape

Sumanta Pal, MD, FASCO;Benjamin Gerendash, MSN, RN, AGACNP-BC;Laura Wood, RN, MSN, OCN

March 31st 2025

Experts discuss first-line treatment strategies for renal cell carcinoma (RCC) in 2025, navigating the evolving therapeutic landscape.

EP. 2: Sequencing Strategies in RCC: Optimizing Treatment Selection After IO-Based Therapy

Sumanta Pal, MD, FASCO;Benjamin Gerendash, MSN, RN, AGACNP-BC;Laura Wood, RN, MSN, OCN

March 31st 2025

Experts discuss sequencing strategies in renal cell carcinoma (RCC), focusing on optimizing treatment selection after immune-oncology (IO)–based therapy.